結核薬の組み合わせの早期の殺菌活性を,トランスレーション性薬理動力学-薬理動力学モデリングアプローチを用いて予測する
bioRxiv : the preprint server for biology
|February 12, 2026
まとめ
新しいトランスレーション・ファルマコキネティック・ファルマコダイナミック (PK-PD) モデリングプラットフォームは,2種類の結核 (TB) 薬の組み合わせによる早期の殺菌活性 (EBA) を正確に予測し,より迅速なレジメン開発を支援しています.
科学分野:
- 薬理学 薬理学とは
- 微生物学 微生物学とは
- 数学的モデリング
背景:
- 肺結核 (TB) 試験では,モノセラピーの早期細菌滅菌活性 (EBA) を評価することが多いが,最適な用量は,薬剤の組み合わせに変換されない場合があります.
- 翻訳的薬理動力学-薬理動力学 (PK-PD) モデリングは,臨床前データからヒトの反応を予測する可能性を示しているが,組み合わせでの使用は限られている.
研究 の 目的:
- 2つの薬剤の結核の組み合わせのEBAを予測するための翻訳単療法PK-PDモデリングプラットフォームの拡張と検証.
- PK-PDモデリングを使用して,ベダキリン,プレトマニド,ラインゾリド,ピラジナミドの間の薬物相互作用を評価する.
主な方法:
- 経験的SUPER方法と機械的汎用薬動力学相互作用モデルを使用して薬物相互作用を特徴づけました.
- 両方の相互作用モデルを翻訳的なPK-PDプラットフォームにリンクし,マウスデータと第IIa期臨床結果 (NC-001研究) を使用して検証しました.
主要な成果:
- ベダキリンとプレトマニドまたはラインゾリドの間の対抗性を含む一貫した相互作用パターンを特定しました.
- ピラジナミドは,ベダキリンとプレトマニドの最も効果的な併用薬でした.
- このプラットフォームは,様々な2種類の薬剤の組み合わせに対する14日間の臨床のコロニー形成単位数を合理的に予測し,ほとんどの観察は95%の予測間隔内にありました.
結論:
- 検証されたトランスレーション PK-PD プラットフォームは,抗結核薬の組み合わせの短期的および長期的な結果を確実に予測します.
- このプラットフォームは,投与量の選択を通知し,効果的な併用薬の特定によって,加速されたレジメンの開発をサポートします.
さらに関連する動画
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
10.3K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.7K
関連する概念動画
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
1
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
1
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
1
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
1
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
1
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
1
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
1
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
1
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
6
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
6
01:28Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
1
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly...
1